Canadian experience managing dose intensity of regorafenib in relation to safety and clinical outcome in metastatic colorectal cancer patients.

e15154Background: Phase III trials CORRECT and CONCUR have shown that Regorafenib confers survival advantage in metastatic colorectal (mCRC) patients. Unfortunately, toxicity often limits its full ...